Loading...
•
Jun 30, 2022
Cytek Biosciences Q2 2022 Earnings Report
Reported a 32% increase in revenue compared to the prior year.
Key Takeaways
Cytek Biosciences reported a total revenue of $40.2 million for Q2 2022, a 32% increase compared to Q2 2021. The company expanded its installed base to 1,356 instruments with 130 instrument placements during the quarter and received CE marking for clinical applications in the European market.
Total revenue was $40.2 million, a 32% increase over the corresponding quarter of 2021.
Gross profit was $24.6 million, a 24% increase compared to $19.7 million in Q2 2021.
Expanded the installed base to 1,356 instruments, with 130 instrument placements during the second quarter
Received CE marking for a series of single-color cFluor® reagents and a 6-color TBNK kit, as Cytek moves to make total cell analysis solutions available for clinical applications in the European market
Revenue by Segment
Forward Guidance
Cytek Biosciences continues to expect full year 2022 revenue to be closer to the high end of the range of $160 million to $168 million.
Positive Outlook
- Full year 2022 revenue expected to be closer to the high end of the range of $160 million to $168 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...